MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
BioCardia Accounts Receivables 2011-2025 | BCDA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables BioCardia
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 K | 201 K | 147 K | 232 K | 147 K | 274 K | 95 K | 74 K | - | - | - | - | 67 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 274 K | 63 K | 144 K |
Quarterly Accounts Receivables BioCardia
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 10 K | - | - | 10 K | 10 K | 58 K | 63 K | 104 K | 115 K | 153 K | 201 K | 300 K | 211 K | 326 K | 147 K | 198 K | 229 K | 190 K | 232 K | 232 K | 232 K | 232 K | 147 K | 147 K | 147 K | 147 K | 274 K | 274 K | 274 K | 274 K | 95 K | 95 K | 95 K | 95 K | 74 K | 74 K | 74 K | 74 K | 107 K | - | - | - | - | - | - | - | - | - | - | - | - | 24 K | 24 K | 24 K | 67 K | 67 K | 67 K | 67 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 326 K | 10 K | 138 K |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
1.78 M | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 3.04 | 4.83 % | $ 235 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Aptevo Therapeutics
APVO
|
5.22 M | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
739 K | - | 3.77 % | $ 22.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
676 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
300 K | - | - | $ 546 M | USA |
 |
Calithera Biosciences
CALA
|
1.54 M | - | -10.95 % | $ 876 K | USA |
 |
Catalyst Biosciences
CBIO
|
1.82 M | $ 12.37 | 2.06 % | $ 814 M | USA |
 |
Celldex Therapeutics
CLDX
|
700 K | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
821 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
136 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
54 M | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Anika Therapeutics
ANIK
|
36 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
CorMedix
CRMD
|
45.4 K | $ 12.19 | 1.75 % | $ 621 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
15.4 M | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
1.65 M | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
18.1 M | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
1.13 M | - | -5.38 % | $ 6.06 M | USA |